Recently, the National Healthcare Security Administration announced the new version of the 2024 medical insurance drug catalog, which will be implemented from January 1, 2025. Which new drugs are included in the reimbursement scope for this adjustment? Recently, the National Healthcare Security Administration held a special event to interpret the relevant situation. Huang Xinyu, Director of the Medical Service Management Department of the National Health Insurance Bureau, introduced that the total number of drugs in the National Health Insurance Drug List will increase to 3159 in 2024, including 1765 western drugs and 1394 traditional Chinese patent medicines and simple preparations; This year, a total of 91 new drugs were added, of which 89 drugs were included through negotiation and bidding, and the remaining two were directly included as national centralized procurement drugs; Among the 91 newly added drugs, 90 are newly launched varieties in the past 5 years, including 38 globally innovative drugs; New drugs are mainly chemical drugs, and the number of biological products is rising rapidly. traditional Chinese patent medicines and simple preparations also has a certain proportion. These drugs are mostly concentrated in tumor, chronic disease, rare disease and other fields, and generally have the characteristics of great clinical value, high innovation and reasonable price. Huang Xinyu introduced that a total of 117 drugs outside the catalog participated in this negotiation bidding, and ultimately 89 drugs were successfully bid, with a success rate of 76% and an average price reduction of 63%, which is basically equivalent to 2023. Among the 28 drugs that failed negotiations, most of them are improved drugs or old drugs that have been on the market abroad for many years, and only 3 are innovative drugs. The vast majority of drugs that failed negotiations can be found in the catalog with similar indications or mechanisms. Only five drugs have certain characteristics in indications or mechanisms, and we regret that negotiations were not successful Huang Xinyu revealed that the failure of negotiations ultimately stems from the inability of pharmaceutical companies to reach an agreement between their expected prices and the willingness of medical insurance providers to pay. For example, in this year's negotiations, there was a drug for treating urticaria that, after being changed from an oral formulation to an injection, increased in price by more than 1000 times and ultimately failed the negotiations. In addition, some imported drugs are affected by the international price system and cannot resonate with the willingness and ability of China's medical insurance fund to pay during the medical insurance negotiation process, ultimately leading to negotiation failure. In addition to newly added drugs, drugs that have already been included in the medical insurance catalog but have exceeded the expiration date of the catalog also need to be renewed. It is reported that there are 140 varieties involved in contract renewal this year, of which 2/3 of the drugs do not require negotiation and can be renewed through a simple renewal process. Through negotiation and bidding, the medical insurance department can screen out drugs that truly have clinical value, high innovation level, and reasonable prices, ensuring that patients can obtain better treatment options Huang Xinyu stated that the adjustment and optimization of the national medical insurance drug catalog in 2024 has improved the structure of the medical insurance catalog, enhanced the level of medication security, effectively supported pharmaceutical innovation, and promoted the development of the pharmaceutical industry. After the implementation of the new version of the medical insurance catalog, the National Medical Insurance Administration will focus on ensuring the supply of drugs, ensuring that patients can buy and use drugs in the medical insurance catalog that can be reimbursed. "Combined with negotiated price reductions and medical insurance reimbursements, it is expected that by 2025, the burden on patients will be reduced by more than 50 billion yuan